Placebo News and Research

RSS

UA researchers one step closer to preventing asthma in children

Efforts to improve the health of children at increased risk for asthma will receive a major boost with the launch of a new University of Arizona Health Sciences-led, federally funded national clinical study. For Fernando D. Martinez, MD, and his colleagues at the UA Asthma and Airway Disease Research Center, this study follows 30 years of research to prevent and cure this chronic disease.

6 May 2016

Caution urged with add-on DPP-4 inhibitors

Physicians should be aware of the need to reduce the dose of sulphonylureas when adding dipeptidyl peptidase-4 inhibitor treatment in patients with Type 2 diabetes, say the authors of a meta-analysis.

5 May 2016

Study shows short-term statin treatment does not benefit heart surgery patients

Giving daily doses of statins for a few days before and after heart surgery does not prevent heart muscle damage or the development of atrial fibrillation (AF), according to an international clinical trial led by the University of Oxford and funded by the British Heart Foundation.

5 May 2016

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

5 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Riluzole drug can reverse key genetic changes linked to Alzheimer's disease

Aging takes its toll on the brain, and the cells of the hippocampus--a brain region with circuitry crucial to learning and memory--are particularly vulnerable to changes that can lead to Alzheimer's disease or cognitive decline. With the hope of counteracting the changes that can lead to these two conditions, researchers at Rockefeller University and their colleagues have begun examining the effects of a drug known to affect this circuitry.

4 May 2016

NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial.

4 May 2016

New study shows women susceptible to pain-relieving placebo effect of vasopressin

A new study in the current issue of Biological Psychiatry suggests that women are particularly susceptible to the pain-relieving placebo effect of vasopressin.

3 May 2016

MAAT may help prevent chemotherapy-induced memory problems in breast cancer survivors

A new analysis indicates that a type of psychotherapy delivered by videoconference may help prevent some of the long-term memory issues caused by chemotherapy.

3 May 2016

Mepolizumab has no hint of added benefit in eosinophilic asthma

The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care now examined in an early benefit assessment whether the drug offers an added benefit for patients in comparison with the appropriate comparator therapy.

3 May 2016

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease.

30 Apr 2016

Black raspberry intake can lower key measure of arterial stiffness in patients with metabolic syndrome

A new study shows that black raspberry extract can significantly lower a key measure of arterial stiffness-an indicator of cardiovascular disease. Black raspberry intake was also associated with increased levels of circulating endothelial progenitor cells (EPCs), which help repair and regenerate damaged arteries, according to the study published in Journal of Medicinal Food, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Medicinal Food website until May 28, 2016.

29 Apr 2016

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

Adults with asthma who were treated with one-dose dexamethasone in the emergency department had only slightly higher relapse than patients who were treated with a 5-day course of prednisone.

28 Apr 2016

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy.

27 Apr 2016

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of inhaled corticosteroid (ICS) reduction among adults with HDM allergy-related asthma not well controlled by ICS, according to a study appearing in the April 26 issue of JAMA.

27 Apr 2016

Updated guidance on botulinum toxin formulations for four indications

The American Academy of Neurology has issued an update to its 2008 guidelines on the use of botulinum toxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache.

27 Apr 2016

Nutritional supplements can enhance effectiveness of antidepressants

An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.

26 Apr 2016

Hydrocortisone drug can also prevent lung damage in premature babies

Research from Ann & Robert H. Lurie Children's Hospital of Chicago conducted in mice shows the drug hydrocortisone -- a steroid commonly used to treat a variety of inflammatory and allergic conditions -- can also prevent lung damage that often develops in premature babies treated with oxygen.

26 Apr 2016

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet.

25 Apr 2016

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer's disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies.

22 Apr 2016

Placebo News and Research

UA researchers one step closer to preventing asthma in children

Caution urged with add-on DPP-4 inhibitors

Study shows short-term statin treatment does not benefit heart surgery patients

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Bayer-new phase 3 liver cancer data

Riluzole drug can reverse key genetic changes linked to Alzheimer's disease

NSCLC MAGE-A3 immunotherapy development halted

New study shows women susceptible to pain-relieving placebo effect of vasopressin

MAAT may help prevent chemotherapy-induced memory problems in breast cancer survivors

Mepolizumab has no hint of added benefit in eosinophilic asthma

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

Black raspberry intake can lower key measure of arterial stiffness in patients with metabolic syndrome

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

Updated guidance on botulinum toxin formulations for four indications

Nutritional supplements can enhance effectiveness of antidepressants

Hydrocortisone drug can also prevent lung damage in premature babies

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News